Opsumit® (macitentan) is an orally available endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target of developing an ERA to address efficacy and safety.
Actelion’s lead product, Tracleer® (bosentan) – an endothelin receptor antagonist – was the first oral treatment approved for PAH.
Miglustat, the active ingredient of Zavesca®, is an orally available molecule with a large volume of distribution, which was developed for the treatment of type 1 Gaucher disease (GD1).
Pure Von Willebrand Factor 1000 IU for prophylaxis & treatment of bleeding of Von Willebrand Factor deficiency Hemophilia.
The leading oral hair lose treatment in Europe with new advanced formula the highest concentration of Cystine
Hematrix patch is certified class III medical device for external use to stop bleeding. Hematrix, ready to use patch consist of spongy polyurethane matrix impregnated with clotting agents such as thrombin, calcium chloride (CaCl2) and epsilon amino caproic acid (EACA).
Beclomethasone dipropionate, the active of Beclomet Nasal spray belongs to the group of medicaments called corticosteroids. Beclomet is indicated for the prophylaxis and treatment of perennial & seasonal allergic rhinitis including hayfever, and vasomotor rhinitis.